SAN DIEGO, CA, United States

Sorrento Therapeutics, Inc.

www.sorrentotherapeutics.com
SAN DIEGO, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Sorrento Therapeutics, Inc. | Date: 2016-11-17

Provided are bispecific antibody compounds having the Formula I: wherein, FAB^(1), FAB^(2), and X are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.


Patent
Sorrento Therapeutics, Inc. | Date: 2017-06-28

There is disclosed compositions and methods relating to or derived from anti- CXCR3 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR3, CXCR3-binding fragments and derivatives of such antibodies, and CXCR3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR3 related disorders or conditions, including various inflammatory disorders and various cancers.


Patent
Sorrento Therapeutics, Inc. | Date: 2017-07-05

There is disclosed compositions and methods relating to or derived from anti-OprF and anti-Oprl antibodies. More specifically, there is disclosed fully human antibodies that bind OprF and Oprl, OprF and Oprl-antibody binding fragments and derivatives of such antibodies, and OprF and Oprl-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having Pseudomonas aeruginosa infections. There is disclosed a method for treating or preventing Pseudomonas aeruginosa infections, wherein the disease is selected from the group consisting of burns, surgical site infections, diabetic foot ulcers, infected wounds, and cystic fibrosis.


Patent
Sorrento Therapeutics, Inc. | Date: 2017-02-22

There is disclosed compositions and methods relating to or derived from anti-CD147 antibodies. More specifically, there is disclosed fully human antibodies that bind CD147, CD147 -binding fragments and derivatives of such antibodies, and CD147 -binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CD147 related disorders or conditions. There is also disclosed a method for treating CD147- expressing tumors, including hepatocellular carcinomas and squamous carcinomas, and non- oncology diseases selected from the group consisting of rheumatoid arthritis, experimental lung injury, atherosclerosis, chronic liver disease induced by hepatitis C vims, ischemic myocardial injury and heart failure.


Patent
Sorrento Therapeutics, Inc. | Date: 2016-02-05

There is disclosed antibody drug conjugates having anthracycline derivative drug moieties that provide improved safety and cell killing efficacy, wherein the anthracycline derivative drug moieties substitute an hydroxymethyl ketone moiety for an hydrazide or hydroxamate moiety. The disclosed cytotoxic agents (i.e., drug moieties) are conjugated to an antibody via either a Cys or a Lys residue. For Lys conjugation, the DAR (drug antibody ratio) of the majority of the ADC is 2 whereas the DAR of the majority of ADC is 4 when conjugation occurs on a Cys residue.


Patent
Sorrento Therapeutics, Inc. | Date: 2017-06-28

There is disclosed compositions and methods relating to or derived from anti-CXCR5 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR5, CXCR5-binding fragments and derivatives of such antibodies, and CXCR5-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR5 related disorders or conditions, including various inflammatory disorders and various cancers.


Patent
Sorrento Therapeutics, Inc. | Date: 2017-03-22

There is disclosed a process for forming chemically-locked bispecific or heterodimer antibodies, preferably in the IgG class, in high specificity and with high homogeneity. More specifically, there is disclosed a chemically-locked bispecific IgG class antibody having a linkage region joined together with bio-orthogonal click chemistry.


Patent
Sorrento Therapeutics, Inc. | Date: 2017-02-22

There is disclosed compositions and methods relating to or derived from anti-WISPl antibodies. More specifically, there is disclosed fully human antibodies that bind WISP1, WISP1 -binding fragments and derivatives of such antibodies, and WISP1 -binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having WISP1 related disorders or conditions. There is also disclosed a method for treating or preventing various cancers or inflammatory diseases and various diseases of the heart, bone/joints or lung.


Patent
Sorrento Therapeutics, Inc. | Date: 2016-10-20

Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.


Patent
Sorrento Therapeutics, Inc. | Date: 2016-10-24

The present invention provides programmable universal cell receptors (PUCRs) comprising a catalytic antibody region, a transmembrane domain and a cytoplasmic domain. The PUCRs disclosed herein may be conjugated to a specificity agent in order to program the receptor for specificity to any molecule of interest. Also provided are nucleic acids encoding such PUCRs, and cells expressing the PUCRs. Such cells may be used in treating a variety of medical conditions and diseases including cancer and infectious diseases.

Loading Sorrento Therapeutics, Inc. collaborators
Loading Sorrento Therapeutics, Inc. collaborators